CAREY STEPHEN P. 4
4 · ANI PHARMACEUTICALS INC · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
ANI Pharmaceuticals (ANIP) CFO Stephen Carey Withholds Shares for Taxes
What Happened
Stephen P. Carey, SVP & Chief Financial Officer of ANI Pharmaceuticals (ANIP), had a total of 5,277 shares disposed via tax withholding following the vesting of restricted stock. On Feb 12, 2026, 2,829 shares were withheld at $76.70 each (value $216,984). On Feb 14, 2026, 2,448 shares were withheld at $77.36 each (value $189,377). Combined, the withheld shares were worth about $406,361. These were tax-withholding dispositions tied to RSU vesting (routine administrative transactions), not open-market sales for investment purposes.
Key Details
- Transaction dates and prices:
- 2026-02-12: 2,829 shares withheld @ $76.70 = $216,984 (footnote F1)
- 2026-02-14: 2,448 shares withheld @ $77.36 = $189,377 (footnote F2)
- Total shares withheld: 5,277; total value ≈ $406,361.
- Shares owned after transaction: Not specified in the filed Form 4.
- Footnotes:
- F1: Withheld in connection with vesting of 6,202 restricted shares (grant previously reported 2025-02-18); exempt under Rule 16(b)-3.
- F2: Withheld in connection with vesting of 5,368 restricted shares (grant previously reported 2024-02-16); exempt under Rule 16(b)-3.
- Filing: Report filed Feb 17, 2026; the Form 4 shows these withholding transactions and does not carry a late-filing flag.
Context
These transactions represent shares withheld to satisfy tax withholding obligations upon RSU vesting (a common administrative step), not discretionary open-market selling or a buy signal. Because the disposals are tax withholdings and are exempt under Rule 16(b)-3, they generally do not reflect insider sentiment about the company’s stock price.
Insider Transaction Report
- Tax Payment
Common Stock
[F1]2026-02-12$76.70/sh−2,829$216,984→ 172,531 total - Tax Payment
Common Stock
[F2]2026-02-14$77.36/sh−2,448$189,377→ 170,083 total
Footnotes (2)
- [F1]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.
- [F2]Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 5,368 shares of restricted stock, the grant of which was previously reported on February 16, 2024.